Revolution Medicines (RVMD) Non-Current Assets (2019 - 2026)

Revolution Medicines' Non-Current Assets history runs 8 years deep, the most recent figure standing at $285.8 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 23.86% year-over-year to $285.8 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 31.83% YoY), while the FY2025 annual figure was $279.5 million, up 21.16% from the prior year.
• Non-Current Assets was $285.8 million for Q1 2026 at Revolution Medicines, up from $279.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $285.8 million in Q1 2026 to a low of $148.4 million in Q1 2022.
• Historically, Non-Current Assets has averaged $196.8 million across 5 years, with a median of $182.4 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets rose 1.24% in 2023, then soared 49.26% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $151.7 million in 2022, then increased by 20.22% to $182.4 million in 2023, then gained by 26.45% to $230.7 million in 2024, then climbed by 21.16% to $279.5 million in 2025, then rose by 2.27% to $285.8 million in 2026.
• The last three Non-Current Assets figures came in at $285.8 million (Q1 2026), $279.5 million (Q4 2025), and $274.4 million (Q3 2025), per Business Quant data.